Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arcus Biosciences Q2 Earnings Call Highlights
Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to break-even earnings per share a year ago.
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.14 per share a year ago.
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Going On With Arcus Biosciences Stock On Wednesday?
Cancer-focused biotech, Arcus Biosciences, Inc. (NYSE:RCUS) stock is trading higher on Wednesday after the company's stock closed lower on Tuesday following a lung cancer trial update.
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?
Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
